Raygent.com Business Development And Intelligence For Healthcare Markets

Home
Buzzwords
About Us
Articles
Archives
Contact Us

Find Us Online:

BIOgraph
Biopharmaceuticals Portfolio
- 2011 Rayno Biopharmaceuticals Portfolio
Diagnostics and Tools Portfolio
- 2011 Rayno Tools and Diagnostics Portfolio
Life Science ETF's and Mutual Funds
- 2009-2010 Life Science Portfolios
Other
- Company Profiles
- Energy
- Macro
- RAG
- Weather
Reading List

Contact Us

Raygent Associates
PO Box 3701
Manhattan Beach, CA 90266
Phone 1-(310)-871-1231

rod @rayno.com

Name
Email
Message
Send a copy of this email to yourself
If you want to submit this form, do not enter anything in this field

Search

Latest
Popular
Tags

Another Daily Reversal : Take More Off in Biotech February 21, 2012
Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen February 17, 2012
No Panic Just Take A Little Off:Caution- Update Rally 2/16 February 15, 2012
Rayno Life Science Portfolio Racks-Up More Gains: REGN, RGDX, SRLS February 13, 2012
Response Genetics Raises $7.5M at $1.50 with New CEO February 2, 2012

Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update April 6, 2011
Three Small Cap Stocks for a Rebound in January: AMRI,ASTX,SRLS-UPDATE 1/5/12 December 14, 2011
Another Big Rally on Europe Non-News: Biotech Sector Lagging October 18, 2011
Rayno 2009 Biotechnology Portfolio-Mid Year Update July 13, 2009
JPMorgan Healthcare Conference-2010 Day One-Monday January 11 January 12, 2010

AACC AACC Effect AACR active cellular immunotherapy ADC antibody-drug conjugates Add new tag Alzheimer Disease antibiotics antibody-drug conjugates antisense antiviral ASCO B2-microglobulin BATTLE Trial bearish nat gas market biodiscovery BIO ETF's biogenerics BIOgraph biomarkers biomedical biosimilars Biotech ETF's biotechnology sector biotech portfolios and ETFs biotech stocks blood transfusion demand BLUD BMY C.difficile cancer vaccines immunotherapy clinical diagnostics companion diagnostics diagnostics genomics genomics personalized medicine genzyme GILD healthcare reform life science ETF's mass spec molecular diagnostics personalized medicine pharmacogenomics targeted therapy

Reuters Healthcare

UPDATE 2-Prevnar trial results needed for CDC recommendation
UPDATE 1-Sequenom seeks injunction in Aria patent case
Obama's Alzheimer's plan focuses on treatment, care
UPDATE 3-Express Scripts 4th-qtr profit lower than expected

About the Author

Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.

Raygent Reads

Bloomberg – Business & Financial News, Breaking News Headlines
GEN | Genetic Engineering & Biotechnology News – Biotech from Bench to Business
GenomeWeb
Investor Uprising – The Individual Investor Intelligence Network
ZeroHedge

Copyright © 2009-2011 Raygent

Raygent Associates | PO Box 3701 Manhattan Beach, CA 90266 | Phone 1-(310)-871-1231 | rod@rayno.com